The sale is small relative to market cap and likely a routine diversification move by an officer. Monitor for any subsequent Form 4 filings to confirm execution and for any pattern of larger insider sales.
NVCR drugs
NVCR drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $11.81entry
- T+1 · 6d ago +1.52%α +0.21% · $11.99
- T+4 · todayOpen
- T+5 · in 8h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Christoph Brackmann, an officer of NovoCure, filed a Form 144 notice of intent to sell 7,343 shares of common stock, with an approximate market value of $94,446 based on a filing date price. The sale represents a small fraction of the company's $1.6B market cap and is a routine insider disposition.
Key Facts
- Reporting owner: Christoph Brackmann, an officer of NovoCure Ltd
- Securities to be sold: 7,343 shares of common stock
- Approximate value of shares: $94,445.67
- Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
- Proposed sale date: November 9, 2026
- Shares acquired on November 4, 2026 via restricted stock from the issuer
- Market cap of NovoCure: $1.6B
Financial Impact
Sale of 7,343 shares valued at ~$94K, representing less than 0.01% of market cap
Risk Factors
- Insider sale intent may signal reduced conviction, though the small size limits concern
- No information on total holdings of the officer to assess proportion sold
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010825 |
| Document: 0001950047-26-010825-index.html | 0001950047-26-010825 |
| Document: 0001950047-26-010825.txt | 0001950047-26-010825 |
Track record
20 reports on NVCR
5 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +19.75% at T+20 after the Feb 27, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $11.83 to $11.30 Now $11.30 −4.48% ▼ −4.48% −2.57% vs SPY
- Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 144 Neutral 2/10 Viewing Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $12.53 to $11.81 Now $11.30 +9.82% ▲ +5.75% +5.38% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $13.11 to $13.15 Now $11.30 −13.81% ▲ +0.31% +2.08% vs SPY
- Oct 1, 20266w ago 8-K Bullish 6/10 Entry $15.92 to $14.94 Now $11.30 −29.02% ▼ −6.16% −6.90% vs SPY
- Sep 9, 20269w ago 8-K Neutral 2/10 Entry $15.63 to $15.35 Now $11.30 −27.70% ▼ −1.79% −1.19% vs SPY
- Sep 1, 202610w ago 8-K Neutral 3/10 Entry $17.38 to $17.83 Now $11.30 −34.98% ▲ +2.59% +2.15% vs SPY
- Jul 23, 202616w ago 8-K Bullish 7/10 Entry $19.99 to $17.65 Now $11.30 −43.47% ▼ −11.71% −11.81% vs SPY
- Jun 30, 202619w ago 8-K Bullish 7/10 Entry $15.15 to $15.78 Now $11.30 −25.41% ▲ +4.16% +4.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers